Padsevonil

Padsevonil is a synaptic vesicle glycoprotein 2A ligand which is under development for the treatment of epilepsy. It is much more potent than earlier SV2A ligands like levetiracetam and brivaracetam. However, in contrast to its predecessors, padsevonil's chemical structure has been modified such that it is no longer a racetam. In addition, padsevonil also interacts with synaptic vesicle glycoprotein 2B and 2C. The drug is being developed by UCB. As of November 2023, it is in phase 2 clinical trials.